Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search

International Journal of Oncology

Volumn 33, Issue 5, 2008, Pages 949-958

  Moribe, Toyoki ^a   Iizuka, Norio ^b   Miura, Toshiaki ^a   Stark, Markus ^a   Tamatsukuri, Shigeru ^a   Ishitsuka, Hideo ^a   Hamamoto, Yoshihiko ^c   Sakamoto, Kazuhiko ^b   Tamesa, Takao ^b   Oka, Masaaki ^b  

^a Research Group   (Japan)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c YAMAGUCHI UNIVERSITY   (Japan)

Author keywords

BASP1; CpG island; Gene expression database; Hepatocellular carcinoma; Methylation profiles; SRD5A2

Indexed keywords

ABC TRANSPORTER; ANGIOGENIN; APOLIPOPROTEIN; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; BISULFITE; BRAIN ACID SOLUBLE PROTEIN 1; CYSTATHIONINE GAMMA LYASE; CYSTEINE DIOXYGENASE; CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; ELECTRON TRANSFERRING FLAVOPROTEIN; ENOLASE; GLUCAGON RECEPTOR; GLUTAMINASE; GLYCINE METHYLTRANSFERASE; GROWTH HORMONE RECEPTOR; HISTIDINE AMMONIALYASE; INHIBITOR OF DIFFERENTIATION 2; LYMPHOCYTE ANTIGEN; MEMBRANE PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 2; UNCLASSIFIED DRUG; BASP1 PROTEIN, HUMAN; NERVE PROTEIN; REPRESSOR PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; CPG ISLAND; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MAPPING; GENETIC ANALYSIS; HUMAN; LIVER CELL CARCINOMA; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN METHYLATION; SEQUENCE ANALYSIS; TUMOR VOLUME; DNA METHYLATION; DNA MICROARRAY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS C; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROMOTER REGION; VIROLOGY;

AGED; CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; TESTOSTERONE 5-ALPHA-REDUCTASE; TUMOR MARKERS, BIOLOGICAL;

EID: 58149180833     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000082     Document Type: Article

References (26)

1. El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750, 1999.
2. Okuda K: Hepatocellular carcinoma. J Hepatol 32: 225-237, 2000.
3. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001.
4. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
5. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.
6. Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319, 2000.
7. Jin Z, Tamura G, Tsuchiya T, Sakata K, Kashiwaba M, Osakabe M and Motoyama T: Adenomatous polyposis coli (APC) gene promoter hy permethylation in primary breast cancers. Br J Cancer 85: 69-73, 2001.
8. Song JZ, Stirzaker C, Harrison J, Melki JR and Clark SJ: Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 21: 1048-1061, 2002.
9. Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim IJ, Shin JH, Han IO and Park JG: Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 23: 6736-6742, 2004.
10. Yu J, Zhang HY, Ma ZZ, Lu W, Wang YF and Zhu JD: Methylation profiling of twenty four genes and the concordant methylation behaveours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res 13: 319-333, 2003.
11. Lehmann U, Berg-Ribbe I, Wingen LU, Brakensiek K, Becker T, Klempnauer J, Schlegelberger B, Kreipe H and Flemming P: Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling. Clin Cancer Res 11: 3654-3660, 2005.
12. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, Takemoto N, Sakamoto K, Hamada K, Ishitsuka H, Miyamoto T, Uchimura S and Hamamoto Y: Self-organizing-map-based molecular signature representing the development of hepatocellular carcinoma. FEBS Lett 579: 1089-1100, 2005.
13. Sobin LH and Wittekind CH: TNM classification of Malignant Tumours. 6th edition. UICC, Wiley-Liss: pp81-83, 2002.
14. Monroe JJ, Manjanatha MG and Skopek TR: Extent of CpG methylation is not proportional to the in vivo spontaneous mutation frequency at transgenic loci in Big Blue™ rodents. Mutat Res 476: 1-11, 2001.
15. Tost J, Schatz P, Schuster M, Berlin K and Gut IG: Analysis and accurate quantification of CpG methylation by MALDI mass spectrometry. Nucleic Acids Res 31: e50, 2003.
16. Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Stark M, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T and Oka M: Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res 26: 4713-4719, 2006.
17. Colella S, Shen L, Baggerly KA, Issa JP and Krahe R: Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 35: 146-150, 2003.
18. Mosevitsky MI, Capony JP, Skladchikova GY, Novitskaya VA, Plekhanov AYu and Zakharov VV: The BASP1 family of myristoylated proteins abundant in axonal termini: primary structure analysis and physico-chemical properties. Biochimie 79: 373-384, 1997.
19. Carpenter B, Hill KJ, Charalambous M, Wagner KJ, Lahiri D, James DI, Andersen JS, Schumacher V, Royer-Pokora B, Mann M, Ward A and Roberts SG: BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1. Mol Cell Biol 24: 537-549, 2004.
20. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE and Reichardt JK: Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354: 975-978, 1999.
21. Nam RK, Toi A, Vesprini D, Ho M, Chu W, Harvie S, Sweet J, Trachtenberg J, Jewett MA and Narod SA: V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 57: 199-205, 2001.
22. Luo J, Dunn TA, Ewing CM, Walsh PC and Isaacs WB: Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 57: 134-139, 2003.
23. Rossi L, Leveri M, Gritti C, De Silvestri A, Zavaglia C, Sonzogni L, Silvestri L, Civardi E, Mondelli MU and Silini EM: Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients. J Hepatol 39: 564-570, 2003.
24. Liu L, Wylie RC, Andrews LG and Tollefsbol TO: Aging, cancer and nutrition: the DNA methylation connection. Mech Ageing Dev 124: 989-998, 2003.
25. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD and Russell DW: Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 92: 903-910, 1993.
26. Bruix J, Boix L, Sala M and Llovet JM: Focus on hepatocellular carcinoma. Cancer Cell 5: 215-219, 2004.